KCT0007909招募中未知
A 24-week randomized, double-eyed, placebo-controlled human body application test for evaluating the efficacy and safety of fermented small black bean on hair healt
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 60(Year)（—）
- 性别
- All
入选标准
- •1) man and woman over the age of 19 and under the age of 60
- •2) Glossy scores according to the visual evaluation classification method correspond to 1 point or more and 3 points or less
- •A person with a total hair damage score of less than 18 points evaluated by exposure to risk factors
- •3) A person capable of maintaining the same hair shape and color during this human body application test
- •4) A person who agrees to participate in the human body application test and prepares a written consent form prior to the commencement of the human body application tes
排除标准
- •1) A person currently being treated for infectious diseases and malignant tumors, including severe cardiovascular system, immune system, respiratory system, hepatometer, kidney and urology system, nervous system, musculoskeletal system, mental system, skin, etc
- •2) As of Visit 1, those who currently have dull dermatitis, scalp psoriasis, and scalp infection
- •3) A person with hair loss diseases such as androgenic alopecia, circular alopecia, resting alopecia, and scarlet alopecia
- •4) A person who plans to manage and operate hair supplies, hair products during this human body application test
- •5) A person who has a problem with food intake for human body application tests due to severe gastrointestinal disorders;
- •6) a smoker
- •7) A person who drinks alcohol equivalent to an average of 40 g or more per day (280 g/week) for men and an average of 20 g or more per day (140 g/week) for women within 4 weeks of visiting;
- •8) A person who has received surgical treatment, such as hair transplantation and scalp reduction, within one year as of Visit 1
- •9) A person who has taken oral Dutasteride or Finasteride within 6 months of visit 1
- •10) A person who has applied topical hair growth agents, wool, and hair growth agents for the last 1 month (30 days) or more as of Visit 1
- •11) A person who uses hair loss relief and hair health functional products within two weeks as of Visit 1
- •12) Those who have been administered systemic steroids, cell death agents, vasodilators, antihypertensive agents, antireflexers, beta receptor blockers, bronchodilators, diuretics, spirolactone, Cimetidine, Diazoxide, Cyclosporine, and Ketoconazole for the last 1 month or more
- •13) A person who has been applying topical steroids to the scalp for the last 1 month (30 days) or more as of Visit 1
- •14) A person who has taken or is currently taking a drug that may affect hair growth within 3 months
- •15) A person who has administered antibiotics and intestinal medications within two weeks as of Visit 1
- •16) Probiotics, Prebiotics within 2 weeks of Visit 1
- •A person who has continuously administered or ingested lactobacillus products (at least four times a week)
- •17) Patients with uncontrolled hypertension (as measured after stabilizing for 10 minutes with systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 100 mmHg or more)
- •18) Uncontrolled diabetics (above 180 mg/dL of fasting blood sugar)
- •19) Those whose creatine is more than twice the upper limit of the organization's normal limit
- •20) A person whose AST (GOT) or ALT (GPT) is more than twice the upper limit of the institution's normal limit
- •21) Those with a TSH of 0.1 µIU/mL or 10 µIU/mL or more
- •22) A person who has participated in other interventional clinical trials (including human application tests) within one month (30 days) of visit 1 or plans to participate in other interventional clinical trials (including human application tests) after the start of this human application test
- •23) A person who is pregnant or who has a plan to become pregnant during the nursing mother or during this human body application test
- •24) A person who is sensitive to or allergic to food ingredients for this human body application test
- •25) A person who judges that the tester is inappropriate for other reasons
研究者
相似试验
尚未招募
不适用
Clinical trial to investigate the efficacy and safety of Cheonwangbosimdan(Soonshimhwan) on mild cognitive impairmentMental and behavioural disordersKCT0006787Dongshin University48
进行中（未招募）
1 期
A two year study to evaluate the effect of tocilizumab in children who have arthritis in several jointsPolyarticular-course juvenile idiopathic arthritisMedDRA version: 13.1Level: LLTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2009-011593-15-BEF. Hoffmann-La Roche Ltd185
进行中（未招募）
1 期
A two year study to evaluate the effect of tocilizumab in children who have arthritis in several jointsPolyarticular-course juvenile idiopathic arthritisMedDRA version: 13.1 Level: LLT Classification code 10059176 Term: Juvenile idiopathic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2009-011593-15-GBF. Hoffmann-La Roche Ltd188
进行中（未招募）
不适用
A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritispolyarticular-course juvenile idiopathic arthritisMedDRA version: 9.1Level: LLTClassification code 10059176Term: Juvenile idiopathic arthritisEUCTR2009-011593-15-FRF. Hoffmann-La Roche Ltd185
进行中（未招募）
不适用
A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritispolyarticular-course juvenile idiopathic arthritisMedDRA version: 9.1Level: LLTClassification code 10059176Term: Juvenile idiopathic arthritisEUCTR2009-011593-15-NLF. Hoffmann-La Roche Ltd185